All In Biotech

NDA 021880 · Bristol Myers Squibb

Revlimid

Lenalidomide · Oral · Thalidomide Analog

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Dec 27, 2005

Approved uses

9

Original approval plus efficacy supplements

Registered trials

1,232

199 Phase 3, 149 recruiting

FAERS reports

425,916

271,846 serious, 54,138 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID ® treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment [see Warnings and Precautions ( 5.1 ), and Medication Guide ( 17 )]. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program,...

What it is approved for

From the label in effect Mar 24, 2023.

REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular...

Mechanism: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 2019 Supplement 57 · Efficacy · priority review OrphanLabelLetter
  • Sep 15, 2017 Supplement 51 · Efficacy · priority review OrphanLabelLetter
  • Feb 22, 2017 Supplement 49 · Efficacy · priority review OrphanLabelLetter
  • Feb 17, 2015 Supplement 41 · Efficacy OrphanLabelLetter
  • Jun 5, 2013 Supplement 34 · Efficacy · priority review OrphanLabelLetter
  • Dec 21, 2011 Supplement 23 · Efficacy LetterLabel
  • Oct 12, 2010 Supplement 18 · Efficacy LabelLetter
  • Jun 29, 2006 Supplement 1 · Efficacy · priority review LabelLetter
  • Dec 27, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelREMSReview
6 products under this application
  • REVLIMID · LENALIDOMIDE 2.5MG · CAPSULE, ORAL · Prescription · TE AB
  • REVLIMID · LENALIDOMIDE 15MG · CAPSULE, ORAL · Prescription · TE AB
  • REVLIMID · LENALIDOMIDE 5MG · CAPSULE, ORAL · Prescription · TE AB
  • REVLIMID · LENALIDOMIDE 20MG · CAPSULE, ORAL · Prescription · TE AB
  • REVLIMID · LENALIDOMIDE 25MG · CAPSULE, ORAL · Prescription · TE AB
  • REVLIMID · LENALIDOMIDE 10MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lenalidomide" as an intervention, any sponsor and status, largest first.

All 1,232 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea31,968
  • fatigue27,107
  • death26,885
  • off label use19,177
  • pneumonia19,040
  • rash18,551
  • plasma cell myeloma17,292
  • neuropathy peripheral12,297
  • white blood cell count decreased12,018
  • constipation11,201
  • nausea10,998
  • asthenia10,240

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200515
2006820
20071,497
20083,609
20092,897
20103,897
20116,340
201211,712
201310,519
20149,108
201534,550
201625,534
201728,602
201826,535
201930,129
202033,935
202152,556
202243,269
202329,356
202430,439
202523,903
202616,693

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Revlimid (Lenalidomide)

2024 spending

$4.18B

Beneficiaries

38,868

239,843 claims

Per beneficiary

$107,531

$854.82 per unit

View as table
YearSpending
2020$5,356,050,275
2021$5,893,547,689
2022$5,935,051,092
2023$3,859,804,789
2024$4,179,511,486

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,222 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.